Showing 1511-1520 of 2494 results for "".
- Horizon Pharma Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at AAOhttps://modernod.com/news/horizon-pharma-announces-presentation-of-results-of-48-week-off-therapy-follow-up-to-the-phase-2-trial-of-teprotumumab-at-aao/2479711/Horizon Pharma announced that more detailed results from the 48 week off-therapy follow-up to the phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the AAO annual meeting, Oct. 27–30, 2018, in Chicago. The data was
- LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Diseasehttps://modernod.com/news/lumithera-announces-first-cpt-code-to-report-photobiomodulation-therapy-in-retinal-disease/2482389/LumiThera announced a new Category III CPT code, effective January 1, 2025. The code, "Photobiomodulation therapy of retina, single session,” was approved by the AMA’s CPT Editorial Panel at the May 2024 meeting.[1] The LIGHTSITE III clinical trial was a
- Iveric Bio Receives Permanent J-code for GA Treatment Izervayhttps://modernod.com/news/iveric-bio-receives-permanent-j-code-for-ga-treatment-izervay/2482181/Iveric Bio, a subsidiary of Astellas, announced that CMS has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macula
- Apellis Receives Permanent J-Code for GA Drug Syfovrehttps://modernod.com/news/apellis-receives-permanent-j-code-for-ga-drug-syfovre/2481844/The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a permanent and product-specific J-code (J2781) for Apellis Pharmaceuticals' Syfovre (pegcetacoplan injection), the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration. The J-code f
- Ophtec: Tiny ID Matrix Code Enables Fast Delivery of Premium IOLshttps://modernod.com/news/ophtec-tiny-id-matrix-code-enables-fast-delivery-of-premium-cataract-iols/2478885/Ophtec announced it has recently integrated a laser marking technology in the production process of its premium cataract IOLs. A micro ID matrix code is imprinted in the IOLs loop junctions by the laser. Using this code, special scanners can identify the IOL
- AMA Issues CPT Category III Codes for Artificial Iris Implantationhttps://modernod.com/news/ama-issues-cpt-category-iii-codes-for-artificial-iris-implantation/2478255/VEO Ophthalmics announced that the American Medical Association (AMA) has issued three CPT codes for the “Insertion of Iris Prosthesis.” The CPT Category III codes are: 0616T, 0617T, and 0618T and are effective July 1, 2020. Earlier this year, the
- EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effecthttps://modernod.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the
- Product Specific J-Code for Omeros’ Omidria is Now in Effecthttps://modernod.com/news/product-specific-j-code-for-omeros-omidria-is-now-in-effect/2476927/Omeros announced that the product specific J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is now effective. Omidria is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce postoperative pain. The new permanent J-code f
- Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-early-assignment-of-permanent-and-specific-j-code-for-dextenza/2476773/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dextenza (dexamethasone ophthalmic insert) 0.4 mg, which is approved for the
- EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code for Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-early-assignment-of-permanent-and-specific-j-code-for-yutiq/2476769/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code, J7314, through the Healthcare Common Procedure Coding System (HCPCS) for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micr